BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bastati N, Beer L, Mandorfer M, Poetter-lang S, Tamandl D, Bican Y, Elmer MC, Einspieler H, Semmler G, Simbrunner B, Weber M, Hodge JC, Vernuccio F, Sirlin C, Reiberger T, Ba-ssalamah A. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid–enhanced MRI Predict Outcomes in Chronic Liver Disease? Radiology 2020;294:98-107. [DOI: 10.1148/radiol.2019190734] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Verde F, Romeo V, Maurea S. Advanced liver imaging using MR to predict outcomes in chronic liver disease: a shift from morphology to function liver assessment. Quant Imaging Med Surg 2020;10:805-7. [PMID: 32269940 DOI: 10.21037/qims.2020.02.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hall RC, Qin J, Laney V, Ayat N, Lu ZR. Manganese(II) EOB-Pyclen Diacetate for Liver-Specific MRI. ACS Appl Bio Mater 2022. [PMID: 35148050 DOI: 10.1021/acsabm.1c01259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Huang M, Lu X, Wang X, Shu J. Diffusion tensor imaging quantifying the severity of chronic hepatitis in rats. BMC Med Imaging 2020;20:74. [PMID: 32615932 DOI: 10.1186/s12880-020-00466-3] [Reference Citation Analysis]
4 Meng D, Liang C, Zheng Y, Wang X, Liu K, Lin Z, Zhu Q, Zhao X. The value of gadobenate dimeglumine-enhanced biliary imaging from the hepatobiliary phase for predicting post-hepatectomy liver failure in HCC patients. Eur Radiol 2022. [PMID: 35639146 DOI: 10.1007/s00330-022-08874-5] [Reference Citation Analysis]
5 Vernuccio F, Cannella R, Bartolotta TV, Galia M, Tang A, Brancatelli G. Advances in liver US, CT, and MRI: moving toward the future. Eur Radiol Exp 2021;5:52. [PMID: 34873633 DOI: 10.1186/s41747-021-00250-0] [Reference Citation Analysis]
6 Beer L, Bastati N, Ba-Ssalamah A, Pötter-Lang S, Lampichler K, Bican Y, Lauber D, Hodge J, Binter T, Pomej K, Simbrunner B, Semmler G, Trauner M, Mandorfer M, Reiberger T. MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. Liver Int 2020;40:2797-807. [PMID: 32816394 DOI: 10.1111/liv.14648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Taouli B, Alves FC. Imaging biomarkers of diffuse liver disease: current status. Abdom Radiol (NY) 2020;45:3381-5. [PMID: 32583139 DOI: 10.1007/s00261-020-02619-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pastor CM, Joly F, Vilgrain V, Millet P. Concentrations and pharmacokinetic parameters of MRI and SPECT hepatobiliary agents in rat liver compartments. Eur Radiol Exp 2021;5:42. [PMID: 34545428 DOI: 10.1186/s41747-021-00236-y] [Reference Citation Analysis]
10 Bastati N, Beer L, Ba-Ssalamah A, Poetter-Lang S, Ambros R, Kristic A, Lauber D, Pomej K, Binter T, Simbrunner B, Semmler G, Balcar L, Bican Y, Hodge JC, Wrba T, Trauner M, Reiberger T, Mandorfer M. Gadoxetic Acid-enhanced MRI-derived Functional Liver Imaging Score (FLIS) and Spleen Diameter Predict Outcomes in ACLD. J Hepatol 2022:S0168-8278(22)00268-9. [PMID: 35525337 DOI: 10.1016/j.jhep.2022.04.032] [Reference Citation Analysis]
11 Río Bártulos C, Senk K, Schumacher M, Plath J, Kaiser N, Bade R, Woetzel J, Wiggermann P. Assessment of Liver Function With MRI: Where Do We Stand? Front Med (Lausanne) 2022;9:839919. [PMID: 35463008 DOI: 10.3389/fmed.2022.839919] [Reference Citation Analysis]
12 Poetter-Lang S, Bastati N, Messner A, Kristic A, Herold A, Hodge JC, Ba-Ssalamah A. Quantification of liver function using gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 2020;45:3532-44. [PMID: 33034671 DOI: 10.1007/s00261-020-02779-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Pötter-Lang S, Ba-Ssalamah A, Bastati N, Messner A, Kristic A, Ambros R, Herold A, Hodge JC, Trauner M. Modern imaging of cholangitis. Br J Radiol 2021;94:20210417. [PMID: 34233488 DOI: 10.1259/bjr.20210417] [Reference Citation Analysis]
14 Vietti Violi N, Argiriadi P, Rosen A, Cherny M, Weiss A, Hernandez-Meza G, Babb JS, Kihira S, Lewis S, Taouli B. Gadoxetate disodium-enhanced MRI: Assessment of arterial phase artifacts and hepatobiliary uptake in a large series. Eur J Radiol 2020;132:109313. [PMID: 33053495 DOI: 10.1016/j.ejrad.2020.109313] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Leao Filho H, de Oliveira CV, Horvat N. Other types of diffuse liver disease: is there a way to do it? Abdom Radiol (NY) 2020;45:3425-43. [PMID: 32306241 DOI: 10.1007/s00261-020-02530-6] [Reference Citation Analysis]
16 Zhou IY, Catalano OA, Caravan P. Advances in functional and molecular MRI technologies in chronic liver diseases. J Hepatol 2020;73:1241-54. [PMID: 32585160 DOI: 10.1016/j.jhep.2020.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
17 Burghart L, Halilbasic E, Schwabl P, Simbrunner B, Stättermayer AF, Petrenko O, Scheiner B, Bauer D, Pinter M, Boztug K, Mandorfer M, Trauner M, Reiberger T. Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. J Gastroenterol 2021. [PMID: 34893924 DOI: 10.1007/s00535-021-01839-3] [Reference Citation Analysis]
18 Gorgen A, Sapisochin G. Re: Hepatobiliary Scintigraphy to Increase the Safety in Right Lobe Living Donor Liver Transplantation: Not Just a Matter of Age and Remnant Volume. Transplantation 2021;105:e64. [PMID: 34048422 DOI: 10.1097/TP.0000000000003659] [Reference Citation Analysis]
19 Elkilany A, Geisel D, Müller T, Fischer A, Denecke T. Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression. Abdom Radiol (NY) 2021;46:979-91. [PMID: 32918576 DOI: 10.1007/s00261-020-02731-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Mandorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. Semin Liver Dis 2020;40:240-55. [PMID: 32557480 DOI: 10.1055/s-0040-1708806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
21 Luo N, Huang X, Ji Y, Jin G, Qin Y, Xiang B, Su D, Tang W. A functional liver imaging score for preoperative prediction of liver failure after hepatocellular carcinoma resection. Eur Radiol 2022. [PMID: 35294586 DOI: 10.1007/s00330-022-08656-z] [Reference Citation Analysis]
22 Lee HJ, Hong SB, Lee NK, Kim S, Seo HI, Kim DU, Han SY, Choo KS. Validation of functional liver imaging scores (FLIS) derived from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Child-Pugh score and FLIS. Eur Radiol 2021. [PMID: 33881570 DOI: 10.1007/s00330-021-07955-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Aslan S, Eryuruk U, Tasdemir MN, Cakir IM. Determining the efficacy of functional liver imaging score (FLIS) obtained from gadoxetic acid-enhanced MRI in patients with chronic liver disease and liver cirrhosis: the relationship between Albumin-Bilirubin (ALBI) grade and FLIS. Abdom Radiol (NY) 2022. [PMID: 35672474 DOI: 10.1007/s00261-022-03557-7] [Reference Citation Analysis]
24 Fahlenkamp UL, Ziegeler K, Adams LC, Böker SM, Engel G, Makowski MR. Intracellular accumulation capacity of gadoxetate: initial results for a novel biomarker of liver function. Sci Rep 2020;10:18104. [PMID: 33093649 DOI: 10.1038/s41598-020-75145-y] [Reference Citation Analysis]
25 Caussy C, Johansson L. Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.Endocrinol Diabetes Metab. 2020;3:e00134. [PMID: 33102797 DOI: 10.1002/edm2.134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]